Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00633425

Enrollment

Registered

2008-03-12

Start date

2002-10-31

Completion date

2003-10-31

Last updated

2008-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

Analyse the glucose profile, based on continuous glucose monitoring by CGMS, in type 2 diabetics inadequately controlled by metformin, before and after the addition of Glimepiride.

Interventions

DRUGGLIMEPIRIDE

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Men or women aged 35 to 70 years * Having given their consent * Type 2 diabetics (HBA1c greater than 6.5% * Fasting glycaemia greater than 1.40 g/l) not controlled by Metformin for at least 6 weeks.

Design outcomes

Primary

Measure	Time frame
Change in interstitial glucose levels between the observation and maintenance phases.	The mean of 24 variations in average hourly glucose readings recorded by CGMS.

Secondary

Measure	Time frame
HbA1c and fasting blood glucose levels.	Measured in the observation and maintenance phases, and change between the two phases.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026